19
1 The Pursuit of Value Is there room (and a role) left for the sales force? Eyeforpharma’s Specialty Pharma Excellence Conference Boston, MA Frank F. Dolan Principal Consultant Twitter: @pharma411

Dolan at specialty pharma commercial effectiveness

Embed Size (px)

Citation preview

Page 1: Dolan at specialty pharma commercial effectiveness

1

The Pursuit of Value

Is there room (and a role) left for the sales force?

Eyeforpharma’s Specialty Pharma Excellence Conference

Boston, MA

Frank F. DolanPrincipal Consultant

Twitter: @pharma411

Page 2: Dolan at specialty pharma commercial effectiveness

Michael Bailey◦ Chief Commercial Officer, AVEO Pharmaceuticals

Jeremy Lutz◦ Senior Director- Decision Support, Cubist

Pharmaceuticals

Brian Irwin◦ Managing Director, Informa Training Partners

Our Panelists

Page 3: Dolan at specialty pharma commercial effectiveness

The data is in…

Courtesy 20th Century Fox

Page 4: Dolan at specialty pharma commercial effectiveness

Right Message

Right People

Right Frequency

Our Forefathers Algorithm

•Key Performance Indicators

•Calls Per Day

•Reach

•Frequency

•Segmentation

•Promotional Sensitivity

•Awareness

•Trial

•Utilization

SalesD

o

M

o

r

e

G

e

t

M

o

r

e

Page 5: Dolan at specialty pharma commercial effectiveness
Page 6: Dolan at specialty pharma commercial effectiveness

High Potential for Developing Perceived Value of Sales Representatives

◦ While sales representatives impact their treatment decisions, MD’s perceive 70% of them to be of only low or medium value to their practice

Aligned to the Customer

Page 7: Dolan at specialty pharma commercial effectiveness

How do MD’s define quality and value?

Product knowledge Disease state knowledge Understanding my needs as a physician Managed care status knowledge Ability to conduct useful face-to-face

interactions Presents relevant product support material

and/or solutions Credibility Appropriate frequency of sales calls

Gaining Competitive Advantage through Value

Page 8: Dolan at specialty pharma commercial effectiveness

What percentage of sales representatives meet your expectations regarding all of the following attributes?

Product knowledge Disease state knowledge Understanding my needs as a physician Managed care status knowledge Ability to conduct useful face-to-face

interactions Presents relevant product support material

and/or solutions Credibility Appropriate frequency of sales calls

Meeting Expectations

Page 9: Dolan at specialty pharma commercial effectiveness

Gold Standard Representative Has:

-Strong Product Knowledge

-Credibility

◦ The vast majority of MD’s see these two attributes as essential for all sales representatives

Rep Essentials

Page 10: Dolan at specialty pharma commercial effectiveness

As a company approaches commercialization with a sales force, what are some approaches to measuring promotional quality?

Panel Question

Page 11: Dolan at specialty pharma commercial effectiveness

The Reality of the Sales Call

◦ MD’s want: #1 gain product knowledge, #2 added value

◦ MD’s say that get a message monolog- NOT product knowledge or value

Conflicting Goals

Page 12: Dolan at specialty pharma commercial effectiveness

Sales Representatives Impact Brand Loyalty

◦ One-third of physicians indicate their prescribing behavior changes when a sales representative changes companies

Key Findings

Page 13: Dolan at specialty pharma commercial effectiveness

In a hospital/institutional selling environment, how do you interpret activity to sales levels?

Panel Question

Page 14: Dolan at specialty pharma commercial effectiveness

Sales Representative Often the Determining Factor in Visits

◦ In 39% of visits, the sales representative, not just the company or products detailed, will determine the institution’s willingness to see a sales representative

Sales Rep as a Critical Success Factor

Page 15: Dolan at specialty pharma commercial effectiveness

Improvements to Perceived Value Opens Doors

◦ Nearly one-third of MD’s give special privileges to sales representatives who meet their expectations on knowledge, interaction frequency, and credibility

Key to Access

61

00

61% of sales representatives currently

do not meet all these needs, presenting

a major opportunity for growth in

physician access

Page 16: Dolan at specialty pharma commercial effectiveness

MD’s Have Control Over Sales Representative Visits

◦ Approximately half of MD’s work in institutions that decide on which sales representatives they engage with on a case-by-case basis

◦ 14% indicate that rep access is determined by formal protocol

Access is Personal

Page 17: Dolan at specialty pharma commercial effectiveness

What investments are companies making to fulfill their pursuit of being more “customer-centric”?

Panel Question

Page 18: Dolan at specialty pharma commercial effectiveness

75% of MD’s give high value representatives more interaction time, more frequent interactions, or both

The Payoff for High value Reps

Page 19: Dolan at specialty pharma commercial effectiveness

Beware activity-to-sales formulas –Quantity centric

Measure promotional quality and value –Customer is scoring you anyway

Customer Listening Metrics is the new Closed Loop Marketing

Where do we go from here